Primary hyperoxaluria: new directions for diagnosis and treatment

Michael B. Ishitani, Carla G. Monico, Dawn S. Milliner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Abstract: Primary hyperoxaluria type 1 (PH1) is a rare genetic autosomal recessive disorder caused by deficient function of the liver-specific metabolic enzyme alanine:glyoxalate aminotransferase (AGT). AGT normally catalyzes the breakdown of glyoxalate to glycine; in PH1, AGT function is abnormal and oxalate accumulates within the body. Oxalate can only be removed from the body by renal excretion, leading to hyperoxaluria with deposition of oxalate in the kidneys and progressive nephrocalcinosis, urolithiasis and renal failure. As renal function declines, oxalate deposition rapidly occurs in tissues throughout the body and results in systemic multiorgan dysfunction and early mortality. Diagnosis of PH1Sn the past was based on clinical presentation in conjunction with high plasma and urinary oxalate measurements. Confirmation of the diagnosis was made by examining liver biopsies for AGT activity. Treatment was primarily based on measures to increase urine flow and decrease oxalate crystallization within the kidney tubules. Pyridoxine therapy was empirically found to be helpful in a number of cases. Renal replacement therapy (dialysis and renal transplantation) met with limited success due to the low rate of oxalate clearance with both haemo- and peritoneal dialysis and the rapid deposition of oxalate within the transplanted kidney. Over the last 5 years, new understanding of the structure and function of AGT and the molecular basis of AGT dysfunction has resulted in the development of new diagnostic techniques which can in some cases eliminate the need for invasive liver biopsies. In addition, characterization of a known genetic polymorphism in combination with a specific amino acid mutation has been found to correlate with response to pyridoxine therapy in a third of patients. Improved long term results in patients who have progressed to renal failure have been reported with combined liver-kidney transplantation in conjunction with aggressive perioperative measures to reduce serum oxalate levels and systemic oxalate stores. Some experience with preemptive liver transplant prior to the development of renal failure has been reported. The role of pre-emptive liver transplantation remains uncertain given the unpredictability of the timing of renal failure and risks of liver transplantation and life-long immune suppression. Continuing efforts at developing specific gene therapy are ongoing.

Original languageEnglish (US)
JournalPaediatrics and Child Health
Volume18
Issue numberSUPPL. 1
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Primary Hyperoxaluria
Oxalates
Alanine Transaminase
Renal Insufficiency
Liver Transplantation
Therapeutics
Pyridoxine
Liver
Kidney
Kidney Transplantation
Direction compound
Hyperoxaluria
Nephrocalcinosis
Kidney Tubules
Biopsy
Urolithiasis
Renal Replacement Therapy
Peritoneal Dialysis
Genetic Polymorphisms
Crystallization

Keywords

  • liver-kidney transplantation, pyridoxine
  • primary hyperoxaluria

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Primary hyperoxaluria : new directions for diagnosis and treatment. / Ishitani, Michael B.; Monico, Carla G.; Milliner, Dawn S.

In: Paediatrics and Child Health, Vol. 18, No. SUPPL. 1, 10.2008.

Research output: Contribution to journalArticle

Ishitani, Michael B. ; Monico, Carla G. ; Milliner, Dawn S. / Primary hyperoxaluria : new directions for diagnosis and treatment. In: Paediatrics and Child Health. 2008 ; Vol. 18, No. SUPPL. 1.
@article{a1c9a2ec6e414d33afaad7e83ff26e97,
title = "Primary hyperoxaluria: new directions for diagnosis and treatment",
abstract = "Abstract: Primary hyperoxaluria type 1 (PH1) is a rare genetic autosomal recessive disorder caused by deficient function of the liver-specific metabolic enzyme alanine:glyoxalate aminotransferase (AGT). AGT normally catalyzes the breakdown of glyoxalate to glycine; in PH1, AGT function is abnormal and oxalate accumulates within the body. Oxalate can only be removed from the body by renal excretion, leading to hyperoxaluria with deposition of oxalate in the kidneys and progressive nephrocalcinosis, urolithiasis and renal failure. As renal function declines, oxalate deposition rapidly occurs in tissues throughout the body and results in systemic multiorgan dysfunction and early mortality. Diagnosis of PH1Sn the past was based on clinical presentation in conjunction with high plasma and urinary oxalate measurements. Confirmation of the diagnosis was made by examining liver biopsies for AGT activity. Treatment was primarily based on measures to increase urine flow and decrease oxalate crystallization within the kidney tubules. Pyridoxine therapy was empirically found to be helpful in a number of cases. Renal replacement therapy (dialysis and renal transplantation) met with limited success due to the low rate of oxalate clearance with both haemo- and peritoneal dialysis and the rapid deposition of oxalate within the transplanted kidney. Over the last 5 years, new understanding of the structure and function of AGT and the molecular basis of AGT dysfunction has resulted in the development of new diagnostic techniques which can in some cases eliminate the need for invasive liver biopsies. In addition, characterization of a known genetic polymorphism in combination with a specific amino acid mutation has been found to correlate with response to pyridoxine therapy in a third of patients. Improved long term results in patients who have progressed to renal failure have been reported with combined liver-kidney transplantation in conjunction with aggressive perioperative measures to reduce serum oxalate levels and systemic oxalate stores. Some experience with preemptive liver transplant prior to the development of renal failure has been reported. The role of pre-emptive liver transplantation remains uncertain given the unpredictability of the timing of renal failure and risks of liver transplantation and life-long immune suppression. Continuing efforts at developing specific gene therapy are ongoing.",
keywords = "liver-kidney transplantation, pyridoxine, primary hyperoxaluria",
author = "Ishitani, {Michael B.} and Monico, {Carla G.} and Milliner, {Dawn S.}",
year = "2008",
month = "10",
doi = "10.1016/S1751-7222(08)70018-0",
language = "English (US)",
volume = "18",
journal = "Paediatrics and Child Health (United Kingdom)",
issn = "1751-7222",
publisher = "Medicine Publishing",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Primary hyperoxaluria

T2 - new directions for diagnosis and treatment

AU - Ishitani, Michael B.

AU - Monico, Carla G.

AU - Milliner, Dawn S.

PY - 2008/10

Y1 - 2008/10

N2 - Abstract: Primary hyperoxaluria type 1 (PH1) is a rare genetic autosomal recessive disorder caused by deficient function of the liver-specific metabolic enzyme alanine:glyoxalate aminotransferase (AGT). AGT normally catalyzes the breakdown of glyoxalate to glycine; in PH1, AGT function is abnormal and oxalate accumulates within the body. Oxalate can only be removed from the body by renal excretion, leading to hyperoxaluria with deposition of oxalate in the kidneys and progressive nephrocalcinosis, urolithiasis and renal failure. As renal function declines, oxalate deposition rapidly occurs in tissues throughout the body and results in systemic multiorgan dysfunction and early mortality. Diagnosis of PH1Sn the past was based on clinical presentation in conjunction with high plasma and urinary oxalate measurements. Confirmation of the diagnosis was made by examining liver biopsies for AGT activity. Treatment was primarily based on measures to increase urine flow and decrease oxalate crystallization within the kidney tubules. Pyridoxine therapy was empirically found to be helpful in a number of cases. Renal replacement therapy (dialysis and renal transplantation) met with limited success due to the low rate of oxalate clearance with both haemo- and peritoneal dialysis and the rapid deposition of oxalate within the transplanted kidney. Over the last 5 years, new understanding of the structure and function of AGT and the molecular basis of AGT dysfunction has resulted in the development of new diagnostic techniques which can in some cases eliminate the need for invasive liver biopsies. In addition, characterization of a known genetic polymorphism in combination with a specific amino acid mutation has been found to correlate with response to pyridoxine therapy in a third of patients. Improved long term results in patients who have progressed to renal failure have been reported with combined liver-kidney transplantation in conjunction with aggressive perioperative measures to reduce serum oxalate levels and systemic oxalate stores. Some experience with preemptive liver transplant prior to the development of renal failure has been reported. The role of pre-emptive liver transplantation remains uncertain given the unpredictability of the timing of renal failure and risks of liver transplantation and life-long immune suppression. Continuing efforts at developing specific gene therapy are ongoing.

AB - Abstract: Primary hyperoxaluria type 1 (PH1) is a rare genetic autosomal recessive disorder caused by deficient function of the liver-specific metabolic enzyme alanine:glyoxalate aminotransferase (AGT). AGT normally catalyzes the breakdown of glyoxalate to glycine; in PH1, AGT function is abnormal and oxalate accumulates within the body. Oxalate can only be removed from the body by renal excretion, leading to hyperoxaluria with deposition of oxalate in the kidneys and progressive nephrocalcinosis, urolithiasis and renal failure. As renal function declines, oxalate deposition rapidly occurs in tissues throughout the body and results in systemic multiorgan dysfunction and early mortality. Diagnosis of PH1Sn the past was based on clinical presentation in conjunction with high plasma and urinary oxalate measurements. Confirmation of the diagnosis was made by examining liver biopsies for AGT activity. Treatment was primarily based on measures to increase urine flow and decrease oxalate crystallization within the kidney tubules. Pyridoxine therapy was empirically found to be helpful in a number of cases. Renal replacement therapy (dialysis and renal transplantation) met with limited success due to the low rate of oxalate clearance with both haemo- and peritoneal dialysis and the rapid deposition of oxalate within the transplanted kidney. Over the last 5 years, new understanding of the structure and function of AGT and the molecular basis of AGT dysfunction has resulted in the development of new diagnostic techniques which can in some cases eliminate the need for invasive liver biopsies. In addition, characterization of a known genetic polymorphism in combination with a specific amino acid mutation has been found to correlate with response to pyridoxine therapy in a third of patients. Improved long term results in patients who have progressed to renal failure have been reported with combined liver-kidney transplantation in conjunction with aggressive perioperative measures to reduce serum oxalate levels and systemic oxalate stores. Some experience with preemptive liver transplant prior to the development of renal failure has been reported. The role of pre-emptive liver transplantation remains uncertain given the unpredictability of the timing of renal failure and risks of liver transplantation and life-long immune suppression. Continuing efforts at developing specific gene therapy are ongoing.

KW - liver-kidney transplantation, pyridoxine

KW - primary hyperoxaluria

UR - http://www.scopus.com/inward/record.url?scp=55049120922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049120922&partnerID=8YFLogxK

U2 - 10.1016/S1751-7222(08)70018-0

DO - 10.1016/S1751-7222(08)70018-0

M3 - Article

AN - SCOPUS:55049120922

VL - 18

JO - Paediatrics and Child Health (United Kingdom)

JF - Paediatrics and Child Health (United Kingdom)

SN - 1751-7222

IS - SUPPL. 1

ER -